Is there adequate evidence for the use of PARPi in combination with ARSI for BRCA+/HRR mutated mCRPC as compared to sequential therapy?

This question is phrased perfectly: the important consideration is whether sequential therapy would be just as good, i.e. the "old" standard of care. Unfortunately, this is not how the three trials cited above were designed. Control-arm HRRm patients were assumed to have access to PARPi post-protoco...

Updated answer:

Recently the BRCAAway trial was published evaluating olaparib vs abiraterone vs olaparib/abiraterone in patients with mCRPC (n=165). This study published the results of the BRCA1 and BRCA2 populations (n=46) as well as other mutations. Cross-over was allowed in the study. The median ...

Absolutely, three very well conducted trials: PROPEL, MAGNITUDE, and TALAPRO-2 have now enriched our treatment armamentarium.